Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis
Antibiotics · 03.04.2023 · 12 (4) · 702
DOI: 10.3390/antibiotics12040702 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 03.04.2023. Verfasst von Carlijn H C Litjens und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Ne…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Radboudumc RIHS Junior Researcher Round.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Linezolid is used off-label for treatment of central nervous system infections. However, its pharmacokinetics and target attainment in cranial cerebrospinal fluid (CSF) in tuberculous meningitis patients is unknown. This study aimed to predict linezolid cranial CSF concentrations and assess attainment of pharmacodynamic (PD) thresholds (AUC:MIC of >119) in plasma and cranial CSF of adults and children with tuberculous meningitis. A physiologically based pharmacokinetic (PBPK) model was developed to predict linezolid cranial CSF profiles based on reported plasma concentrations. Simulated steady-state PK curves in plasma and cranial CSF after linezolid doses of 300 mg BID, 600 mg BID, and 1200 mg QD in adults resulted in geometric mean AUC:MIC ratios in plasma of 118, 281, and 262 and mean cranial CSF AUC:MIC ratios of 74, 181, and 166, respectively. In children using ~10 mg/kg BID linezolid, AUC:MIC values at steady-state in plasma and cranial CSF were 202 and 135, respectively. Our model predicts that 1200 mg per day in adults, either 600 mg BID or 1200 mg QD, results in reasonable (87%) target attainment in cranial CSF. Target attainment in our simulated paediatric population was moderate (56% in cranial CSF). Our PBPK model can support linezolid dose optimization efforts by simulating target attainment close to the site of TBM disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
- Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
- Department of Pharmacy, Uppsala University, 75123 Uppsala, Sweden.
ORCID-Profile: Elin M Svensson, Frans G M Russel
Förderung
- Radboudumc RIHS Junior Researcher Round
Zitieren
APA
Litjens, C. H. C., Verscheijden, L. F. M., Svensson, E. M., van den Broek, P. H. H., van Hove, H., Koenderink, J. B., Russel, F. G. M., Aarnoutse, R. E., & Te Brake, L. H. M. (2023). Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis. Antibiotics, 12(4), 702. https://doi.org/10.3390/antibiotics12040702
Vancouver
Litjens CHC, Verscheijden LFM, Svensson EM, van den Broek PHH, van Hove H, Koenderink JB, et al. Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis. Antibiotics. 2023;12(4):702. doi:10.3390/antibiotics12040702
BibTeX
@article{Litjens2023,
author = {Litjens, Carlijn H C and Verscheijden, Laurens F M and Svensson, Elin M and van den Broek, Petra H H and van Hove, Hedwig and Koenderink, Jan B and Russel, Frans G M and Aarnoutse, Rob E and Te Brake, Lindsey H M},
title = {Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis},
journal = {Antibiotics},
year = {2023},
volume = {12},
number = {4},
pages = {702},
doi = {10.3390/antibiotics12040702}
}
EUVIMED